Necchi, A., Jong, J. J. D., Proudfoot, J. A., Mercinelli, C., Maiorano, B. A., Cigliola, A., Tateo, V., Piacentini, M., Tomasi, E., Davicioni, E., Moschini, M., Brembilla, G., Colecchia, M., Cobelli, F. D., Briganti, A., Ross, J. S., Pavlick, D. C., Montorsi, F. (2026). Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.769